Cosmos Health Inc. Stock Price, News & Analysis

Cosmos Health (NASDAQ:COSM) has announced that its subsidiary, Cana Laboratories, has secured a new 10-year contract manufacturing agreement with Provident Pharmaceuticals to produce four pharmaceutical products. The agreement covers the production of 8 million packs over the contract period, consisting of:

- Miorelique® (Baclofen oral solution): 200,000 packs annually
- BE Union F.C. (Vitamin B-complex tablets): 400,000 packs annually
- Certorun (Sertraline capsules) in 50mg and 100mg: 200,000 combined packs annually

Cana Laboratories currently operates with two shifts and has the capacity to expand to three shifts to meet increased demand. The products are generic versions of established medications Lioresal, Neurobion, and Zoloft, respectively.

Cosmos Health (NASDAQ:COSM) has received an initial purchase order worth $578,460 from Al Rabwa International Services and Trading for its Sky Premium Life® food supplement products in Qatar. The order encompasses 35 of the Company's 79 SKUs, with Al Rabwa receiving exclusivity rights for distribution.

Al Rabwa, established in 2013, has grown into a leading distribution company in Qatar, serving retail, food service, and wholesale sectors. The company maintains a broad product portfolio supported by global suppliers and producers, along with professional sales, marketing, and customer service operations.

Cosmos Health (NASDAQ:COSM) has filed a patent application (N2039644) for a multiple sclerosis (MS) treatment, leveraging its AI-powered Cloudscreen drug repurposing platform. The initiative stems from the company's collaboration with Cloudpharm and the National Hellenic Research Foundation, supported by NLO's pharma patent experts.

The patent application is based on data-driven in silico evidence and simulations, along with experimental validation, identifying a unique mechanism of action in a repurposed marketed drug for MS treatment. This development targets the growing MS market, which was valued at $25.94 billion in 2023 and is expected to grow at a 5.9% CAGR from 2024 to 2030.

Multiple sclerosis, affecting 2.9 million people globally as of 2023, is a chronic autoimmune disorder impacting the central nervous system. The global market growth is driven by therapeutic advancements, increased healthcare investments, and ongoing research addressing unmet patient needs.

Cosmos Health (NASDAQ:COSM) has secured a €2.2 million (approximately $2.29 million) bond loan through its subsidiary CosmoFarm from a European bank. The loan, announced on January 27, 2025, will be issued in two tranches: €700,000 in Series A Bonds and €1.5 million in Series B Bonds.

The bond loan, maturing on January 27, 2030, carries an interest rate of 2.95% plus the 6-month Euribor rate, payable semi-annually. Series A Bonds will be repaid in 10 equal semi-annual installments, while Series B Bonds are due at maturity. The loan is secured by CosmoFarm's building and includes an option to upsize for additional capital.

The proceeds will support strategic growth initiatives and provide working capital as the company aims to achieve positive operating cash flow.

Cosmos Health (NASDAQ:COSM) has filed a new patent application (N2039646) for allergic inflammation therapy, developed through AI drug repurposing in collaboration with Cloudpharm and the National Hellenic Research Foundation. The patent leverages their AI-powered Cloudscreen platform and experimental data to repurpose an existing marketed drug, targeting key inflammatory pathways through a novel mechanism.

The initiative addresses a significant market opportunity, as allergic conditions affect 10-30% of the global population according to BMJ Open 2024. The global allergy treatment market, valued at $23.5 billion in 2024, is projected to reach $37.0 billion by 2033, growing at a CAGR of 4.92%.

Cosmos Health (NASDAQ:COSM) has expanded its exclusive distribution agreement with Virax Biolabs for Avian Influenza Virus Real-Time PCR Kits to include Saudi Arabia, UAE, Qatar, and Kuwait. This expansion follows the previous agreement announced on January 13, 2025, which was to Oman and Bahrain. Under the new agreement, Cosmos Health gains authorization to import, sell, and distribute ViraxClear-branded kits throughout all GCC countries.

Cosmos Health (NASDAQ:COSM) has secured buy-out rights and exclusive licensing for two WIPO-patented anticancer drugs targeting prostate, ovarian, and colorectal cancers. The patents, valued at approximately $24.61 million by a global audit firm, can be acquired for $7.81 million, potentially adding $16.80 million to the Company's net worth.

The first therapy is protected by WIPO patent WO 2017/001439, valid in the EU, USA, Canada, Japan, China, and Australia. The second therapy is covered by EU patent EP3484892 and filed under WO 2018/011414 A1. Both therapies are set to begin Clinical Phase I trials.

The target markets show significant growth potential, with projections for 2030 including: ovarian cancer drug market reaching $6.3 billion (14.6% CAGR), prostate cancer therapeutics reaching $21.48 billion (8.4% CAGR), and colorectal cancer therapeutics achieving $16.7 billion (4.7% CAGR).

Cosmos Health (NASDAQ:COSM) announced that CEO Greg Siokas has acquired 647,809 common shares valued at $425,000 through six transactions between December 20, 2024, and January 17, 2025. Following these purchases, Siokas's beneficial ownership in the company has increased to 4,164,789 common shares.

The CEO expressed enthusiasm about the company's future prospects and highlighted his continued commitment, noting his total personal investment of over $17 million since the company's inception. Siokas emphasized that Cosmos Health is at a transformative moment, focusing on advancing their strategy, driving projects forward, and expanding their brands globally.

Cosmos Health (NASDAQ:COSM) has secured a distribution agreement with Virax Biolabs for Avian Influenza Virus (AIV) Real-Time PCR Kits. The agreement grants exclusive distribution rights in Greece and Cyprus, along with non-exclusive rights in 12 European countries and 2 GCC nations (Oman and Bahrain).

The RT-PCR tests detect RNA from AIV, including H5, H7, and H9 subtypes, particularly the H5N1 strain. These kits enable healthcare professionals to quickly identify infections in individuals exposed to infected livestock or high-risk environments. Under the agreement, Cosmos Health will handle import, sales, and distribution, while Virax will manage regulatory compliance and documentation for product approvals.

The partnership aims to enhance global preparedness against avian influenza outbreaks by providing specialized testing capabilities that can differentiate between various strains, supporting rapid response and intervention in healthcare systems.